Continuous and Semi-Continuous Bioprocessing Market

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the continuous and semi-continuous bioprocessing market in the short to mid-term, and long term.

Chapter 3 provides a general introduction to continuous bioprocessing technology. The chapter describes the historical evolution of continuous bioprocessing in the pharmaceutical industry. It features a brief overview of the regulatory landscape, the early adopters of this technology, opportunities and key challenges associated with the adoption of these techniques. The chapter also discusses the future perspectives of the continuous and semi-continuous bioprocessing market.

Chapter 4 provides an overview of the overall landscape of the companies with capabilities for continuous and semi-continuous bioprocessing, including information on around 60 players engaged in this domain. Additionally, it features an in-depth analysis of the companies, based on a number of parameters, such as year of establishment, company size, type of manufacturer (innovator / drug developer and contract service provider), scale of operation (preclinical, clinical and commercial), location of headquarters, location of continuous and semi-continuous bioprocessing facilities of innovators, location of continuous and semi-continuous bioprocessing facilities of contract service providers, type of facility (modular and conventional), type of bioreactor (single-use and stainless steel), stage of bioprocess (upstream and downstream), primary continuous and semi-continuous bioprocessing (continuous cell culture, continuous clarification / harvesting, continuous purification, process analytical technology and others), secondary continuous and semi-continuous bioprocessing (N-1 stage perfusion, N stage perfusion, continuous concentrated fed-batch, continuous cell retention, continuous centrifugation, continuous chromatography and continuous viral filtration), types of biologics manufactured (antibodies, proteins / peptides, vectors, enzymes and others) and details on the continuous and semi-continuous production capacity.

Chapter 5 includes tabulated profiles of the key stakeholder that have adopted the continuous and semi-continuous bioprocessing technologies and are active in the aforementioned market in North America. Each profile features a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing related capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.

Chapter 6 includes tabulated profiles of the key stakeholder that have adopted the continuous and semi-continuous bioprocessing technologies and are active in the aforementioned market in Europe. Each profile features a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing related capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.

Chapter 7 includes tabulated profiles of the key stakeholder that have adopted the continuous and semi-continuous bioprocessing technologies and are active in the aforementioned market in Asia-Pacific. Each profile features a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing related capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.

Chapter 8 highlights the key initiatives taken by the leading pharmaceutical companies (in terms of revenues generated), taking into consideration both partnered as well as in-house projects.

Chapter 9 is a case study providing information on more than 80 continuous manufacturing equipment for biologics. It features a detailed analysis based on the type of equipment, type of manufacturing process (continuous and batch-continuous) and stage of bioprocess (upstream process and downstream process) and the scale of operation (preclinical / clinical and commercial). Further, the chapter provides information on equipment provider(s) along with information on their year of establishment, company size, location of headquarters and key players in this domain.

Chapter 10 presents an insightful analysis of the cost saving potential associated with the adoption of continuous and semi-continuous bioprocessing technologies.

Chapter 11 features a detailed analysis of the global, continuous upstream bioprocessing capacity based on the capacities of various industry stakeholders (as available on their respective company websites). The study examines the distribution of capacity, based on the company size (small, mid-sized and large), type of manufacturer (innovator / drug developer and contract service provider), scale of operation (preclinical, clinical and commercial), location of headquarters (North America, Europe and Asia-Pacific) and location of continuous and semi-continuous bioprocessing facilities (North America, Europe and Asia-Pacific).

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of the continuous and semi-continuous bioprocessing market till the year 2030. In order to provide an informed future outlook, our projections have been segmented across [A] type of manufacturer (innovator / drug developer and contract service provider), [B] company size (large, mid-sized and small), [C], scale of operation (preclinical / clinical and commercial), [D] stage of bioprocess (upstream and downstream), and [E] key geographical regions (North America, Europe and Asia-Pacific).

Chapter 13 is a summary of the overall report wherein we have mentioned all the key facts and figures described in the chapters. The chapter also highlights the important evolutionary trends that were identified during our research and are expected to influence the continuous and semi-continuous bioprocessing market in the future.

Chapter 14 contains the interview transcripts of the discussions held with key stakeholders engaged in this domain. In this study, we spoke to Jon Coffman (Senior Director of Bioprocess Technology and Engineering, AstraZeneca), Ehsan Mahdinia (Assistant professor, Albany College of Pharmacy and Health Sciences) and Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences).

Chapter 15 is an appendix, that contains tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Continuous Bioprocessing
3.3. Continuous Processing in the Pharmaceutical Industry
3.3.1. Regulatory Landscape
3.3.2. Early Adopters of the Technology
3.3.3. Anticipated Shift from Batch Processing
3.3.4. Advantages of Continuous Processing 
3.3.5. Key Challenges Associated with Continuous Processing
3.3.6. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Continuous and Semi-Continuous Bioprocessing: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Type of Manufacturer
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Company Size and Type of Manufacturer
4.2.6. Analysis by Location of Headquarters
4.2.7. Analysis of Locations of Continuous and Semi-Continuous Bioprocessing Facilities of Innovators
4.2.8. Analysis of Locations of Continuous and Semi-Continuous Bioprocessing Facilities of Contract Service Providers
4.2.9. Analysis by Type of Facility
4.2.10. Analysis by Type of Bioreactor
4.2.11. Analysis by Stage of Bioprocess
4.2.11.1. Primary Continuous and Semi-Continuous Bioprocessing
4.2.11.2. Secondary Continuous and Semi-Continuous Bioprocessing
4.2.12. Analysis by Types of Biologics Manufactured
4.2.13. Information on Production Capacity 

5. CONTINUOUS BIOPROCESSING IN NORTH AMERICA: COMPANY PROFILES
5.1. Chapter Overview
5.2. AGC Biologics
5.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.2.2. Recent Developments and Future Outlook

5.3. Biogen
5.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.3.2. Recent Developments and Future Outlook

5.4. Bristol-Myers Squibb
5.4.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.4.2. Recent Developments and Future Outlook

5.5. Sanofi Genzyme
5.5.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.5.2. Recent Developments and Future Outlook

6. CONTINUOUS BIOPROCESSING IN EUROPE: COMPANY PROFILES
6.1. Chapter Overview
6.2. FUJIFILM Diosynth Biotechnologies
6.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.2.2. Recent Developments and Future Outlook

6.3. Merck KGaA
6.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.3.2. Recent Developments and Future Outlook

6.4. Novasep
6.4.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.4.2. Recent Developments and Future Outlook

6.5. UCB Pharma
6.5.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.5.2. Recent Developments and Future Outlook

7. CONTINUOUS BIOPROCESSING IN ASIA-PACIFIC: COMPANY PROFILES
7.1. Chapter Overview
7.2. Enzene Biosciences
7.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
7.2.2. Recent Developments and Future Outlook

7.3. WuXi Biologics
7.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
7.3.2. Recent Developments and Future Outlook

8. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS BIOPROCESSING CAPABILITIES
8.1. Chapter Overview
8.2. Continuous Manufacturing Initiatives of Leading Companies
8.2.1. AbbVie
8.2.1.1. Partnered Initiatives 
8.2.1.2. In-House Initiatives

8.2.2. Amgen
8.2.2.1. Partnered Initiatives
8.2.2.2. In-House Initiatives

8.2.3. Bristol-Myers Squibb
8.2.3.1. Partnered Initiatives
8.2.3.2. In-House Initiatives

8.2.4. GlaxoSmithKline
8.2.4.1. Partnered Initiatives
8.2.4.2. In-House Initiatives

8.2.5. Merck
8.2.5.1. Partnered Initiatives
8.2.5.2. In-House Initiatives

8.2.6. Novartis
8.2.6.1. Partnered Initiatives
8.2.6.2. In-House Initiatives

8.2.7. Pfizer
8.2.7.1. Partnered Initiatives
8.2.7.2. In-House Initiatives

8.2.8. Roche
8.2.8.1. Partnered Initiatives
8.2.8.2. In-House Initiatives

8.2.9. Sanofi
8.2.9.1. Partnered Initiatives
8.2.9.2. In-House Initiatives

9. CONTINUOUS MANUFACTURING EQUIPMENT FOR BIOLOGICS: MARKET LANDSCAPE
9.1. Chapter Overview
9.2. Continuous Manufacturing Equipment for Biologic Drugs: Overall Market Landscape
9.2.1. Analysis by Type of Equipment
9.2.2. Analysis by Type of Manufacturing Process
9.2.3. Analysis by Stage of Bioprocess
9.2.4. Analysis by Scale of Operation

9.3. Continuous Manufacturing Equipment Providers for Biologics
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.3.4. Analysis by Prominent Continuous Manufacturing Equipment Providers

10. COST SAVING ANALYSIS
10.1. Chapter Overview
10.2 Technologies Involved in Continuous and Semi-Continuous Bioprocessing
10.3 Cost Saving Potential of Continuous and Semi-Continuous Bioprocessing
10.3.1. Potential Cost Savings in Upstream Processes
10.3.2. Potential Cost Savings in Downstream Processes

10.4. Key Assumptions and Methodology
10.5 Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocesses, 2021-2030
10.6 Concluding Remarks

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3.1. Global, Continuous and Semi-Continuous Bioprocessing Capacity
11.3.2. Analysis by Company Size
11.3.3. Analysis by Type of Manufacturer
11.3.4. Analysis by Company Size and Type of Manufacturer
11.3.4. Analysis by Scale of Operation
11.3.5. Analysis by Location of Headquarters
11.3.6. Analysis by Location of Continuous and Semi-Continuous Bioprocessing Facilities

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Overall Continuous and Semi-Continuous Bioprocessing Market, 2021-2030
12.3.1. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer
12.3.2. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Company Size
12.3.3. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Scale of Operation
12.3.4. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Stage of Bioprocess
12.3.5. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Key Geographical Regions

12.4. Continuous Upstream Bioprocessing Market, 2021-2030
12.4.1. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer
12.4.2. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Company Size
12.4.3. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation
12.4.4. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Key Geographical Regions

12.5. Continuous Downstream Bioprocessing Market, 2021-2030
12.5.1. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer
12.5.2. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Company Size
12.5.3. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation
12.5.4. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Key Geographical Regions

13. CONCLUSION

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. AstraZeneca
14.2.1. Overview of Company / Organization 
14.2.2. Interview Transcript: Jon Coffman, Senior Director of Bioprocess Technology and Engineering

14.3. Enzene Biosciences
14.3.1. Overview of Company / Organization 
14.3.2. Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer

14.4. Albany College of Pharmacy and Health Sciences
14.4.1. Overview of Company / Organization 
14.4.2. Interview Transcript: Ehsan Mahdinia, Assistant Professor

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Advantages of Continuous Bioprocessing
Figure 4.1 Continuous and Semi-Continuous Bioprocessing: Distribution by Year of Establishment
Figure 4.2 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size
Figure 4.3 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Manufacturer
Figure 4.4 Continuous and Semi-Continuous Bioprocessing: Distribution by Scale of Operation
Figure 4.5 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size and Type of Manufacturer
Figure 4.6 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Headquarters
Figure 4.7 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Facilities of Innovators
Figure 4.8 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Contract Service Providers
Figure 4.9 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility
Figure 4.10 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Bioreactor
Figure 4.11 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility and Type of Bioreactor
Figure 4.12 Continuous and Semi-Continuous Bioprocessing: Distribution by Stage of Bioprocess
Figure 4.13 Continuous and Semi-Continuous Bioprocessing: Distribution by Primary Continuous and Semi-Continuous Bioprocessing
Figure 4.14 Continuous and Semi-Continuous Bioprocessing: Distribution by Secondary Continuous and Semi-Continuous Bioprocessing
Figure 4.15 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Biologic Manufactured
Figure 8.1 Continuous Manufacturing Initiatives: AbbVie
Figure 8.2 Continuous Manufacturing Initiatives: Amgen
Figure 8.3 Continuous Manufacturing Initiatives: Bristol-Myers Squibb
Figure 8.4 Continuous Manufacturing Initiatives: GlaxoSmithKline
Figure 8.5 Continuous Manufacturing Initiatives: Merck
Figure 8.6 Continuous Manufacturing Initiatives: Novartis
Figure 8.7 Continuous Manufacturing Initiatives: Pfizer
Figure 8.8 Continuous Manufacturing Initiatives: Roche
Figure 8.9 Continuous Manufacturing Initiatives: Sanofi
Figure 9.1 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Equipment
Figure 9.2 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Manufacturing Process
Figure 9.3 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Stage of Bioprocess
Figure 9.4 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Scale of Operation
Figure 9.5 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Year of Establishment
Figure 9.6 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Company Size
Figure 9.7 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Location of Headquarters
Figure 9.8 Key Players: Distribution by Continuous Manufacturing Equipment for Biologic Drugs
Figure 10.1 Technologies Involved: Hybrid vs Fully Integrated Continuous Technologies
Figure 10.2 Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocess Techniques, 2021-2030 (USD Billion)
Figure 11.1 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (Range of Capacity)
Figure 11.2 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (in Kg/Year)
Figure 11.3 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Type of Manufacturer (in Kg/Year)
Figure 11.4 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size and Type of Manufacturer (in Kg/Year)
Figure 11.5 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Scale of Operation (in Kg/Year)
Figure 11.6 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Headquarters (in Kg/Year)
Figure 11.7 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Continuous and Semi-Continuous Bioprocessing Facilities (in Kg/Year)
Figure 12.1 Overall Continuous and Semi-Continuous Bioprocessing Market, 2021-2030 (USD Million)
Figure 12.2 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Figure 12.3 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
Figure 12.4 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 12.5 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Stage of Bioprocess (USD Million)
Figure 12.6 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Figure 12.7 Continuous Upstream Bioprocessing Market, 2021-2030 (USD Million)
Figure 12.8 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Figure 12.9 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
Figure 12.10 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 12.11 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Figure 12.12 Continuous Downstream Bioprocessing Market, 2021-2030 (USD Million)
Figure 12.13 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Figure 12.14 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
Figure 12.15 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 12.16 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Figure 13.1 Concluding Remarks: Market Landscape
Figure 13.2 Concluding Remarks: Capacity Analysis
Figure 13.3 Concluding Remarks: Recent Expansions
Figure 13.4 Concluding Remarks: Cost Saving Analysis
Figure 13.5 Concluding Remarks: Market Sizing and Opportunity Analysis for Continuous and Semi-Continuous Bioprocessing Market

List Of Tables

Table 3.1 Early Adopters of Continuous Bioprocess Technology
Table 3.2 Batch Processing Technique versus Continuous Processing Technique: Comparison of Characteristics
Table 4.1 List of Companies with Expertise in Continuous and Semi-Continuous Bioprocessing
Table 4.2 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Scale of Operation
Table 4.3 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Type of Facility and Type of Bioreactor
Table 4.4 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Stage of Bioprocess
Table 4.5 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Primary Continuous and Semi-Continuous Bioprocessing
Table 4.6 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Secondary Continuous and Semi-Continuous Bioprocessing
Table 4.7 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Types of Biologics Manufactured
Table 4.8 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Production Capacity
Table 5.1 AGC Biologics: Company Snapshot
Table 5.2 AGC Biologics: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.3 AGC Biologics: Recent Developments and Future Outlook
Table 5.4 Biogen: Company Snapshot
Table 5.5 Biogen: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.6 Biogen: Recent Developments and Future Outlook
Table 5.7 Bristol-Myers Squibb: Company Snapshot
Table 5.8 Bristol-Myers Squibb: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.9 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 5.10 Sanofi Genzyme: Company Snapshot
Table 5.11 Sanofi Genzyme: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.12 Sanofi Genzyme: Recent Developments and Future Outlook
Table 6.1 FUJIFILM Diosynth Biotechnologies: Company Snapshot
Table 6.2 FUJIFILM Diosynth Biotechnologies: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.3 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 6.4 Merck KGaA: Company Snapshot
Table 6.5 Merck KGaA: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.6 Merck KGaA: Recent Developments and Future Outlook
Table 6.7 Novasep: Company Snapshot
Table 6.8 Novasep: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.9 Novasep: Recent Developments and Future Outlook
Table 6.10 UCB Pharma: Company Snapshot
Table 6.11 UCB Pharma: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.12 UCB Pharma: Recent Developments and Future Outlook
Table 7.1 Enzene Biosciences: Company Snapshot
Table 7.2 Enzene Biosciences: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 7.3 Enzene Biosciences: Recent Developments and Future Outlook
Table 7.4 WuXi Biologics: Company Snapshot
Table 7.5 WuXi Biologics: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 7.6 WuXi Biologics: Recent Developments and Future Outlook
Table 8.1 AbbVie: Partnered Initiatives
Table 8.2 AbbVie: In-House Initiatives
Table 8.3 Amgen: Partnered Initiatives
Table 8.4 Amgen: In-House Initiatives
Table 8.5 Bristol-Myers Squibb: Partnered Initiatives
Table 8.6 Bristol-Myers Squibb: In-House Initiatives
Table 8.7 GlaxoSmithKline: Partnered Initiatives
Table 8.8 GlaxoSmithKline: In-House Initiatives
Table 8.9 Merck: Partnered Initiatives
Table 8.10 Merck: In-House Initiatives
Table 8.11 Novartis: Partnered Initiatives
Table 8.12 Novartis: In-House Initiatives
Table 8.13 Pfizer: Partnered Initiatives
Table 8.14 Pfizer: In-House Initiatives
Table 8.15 Roche: Partnered Initiatives
Table 8.16 Roche: In-House Initiatives
Table 8.17 Sanofi: Partnered Initiatives
Table 8.18 Sanofi: In-House Initiatives
Table 9.1 Continuous Manufacturing Equipment for Biologics: Information on Type of Equipment, Type of Manufacturing Process and Stage of Bioprocess
Table 9.2 Continuous Manufacturing Equipment for Biologics: Information on Scale of Operation and Throughput / Capacity
Table 9.3 Continuous Manufacturing Equipment Providers for Biologics: Information of Year of Establishment, Company Size and Location of Headquarters
Table 10.1 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential Associated with Continuous Upstream Process
Table 10.2 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential of AcuSyst Perfusion Bioreactors
Table 10.3 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential Associated with Continuous Downstream Process
Table 11.1 Global Continuous and Semi-Continuous Bioprocessing Capacity: Average Upstream Capacity by Company Size (Sample Data Set)
Table 14.1 AstraZeneca: Company / Organization Snapshot
Table 14.2 Enzene Biosciences: Company / Organization Snapshot
Table 14.3 Albany College of Pharmacy and Health Sciences: Company / Organization Snapshot
Table 15.1 Continuous and Semi-Continuous Bioprocessing: Distribution by Year of Establishment
Table 15.2 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size
Table 15.3 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Manufacturer
Table 15.4 Continuous and Semi-Continuous Bioprocessing: Distribution by Scale of Operation
Table 15.5 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size and Type of Manufacturer
Table 15.6 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Headquarters
Table 15.7 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Innovators
Table 15.8 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Contract Service Providers
Table 15.9 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility
Table 15.10 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Bioreactor
Table 15.11 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility and Type of Bioreactor
Table 15.12 Continuous and Semi-Continuous Bioprocessing: Distribution by Stage of Bioprocess
Table 15.13 Continuous and Semi-Continuous Bioprocessing: Distribution by Primary Continuous and Semi-Continuous Bioprocessing
Table 15.14 Continuous and Semi-Continuous Bioprocessing: Distribution by Secondary Continuous and Semi-Continuous Bioprocessing
Table 15.15 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Biologic Manufactured
Table 15. 16 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Equipment
Table 15.17 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Manufacturing Process
Table 15.18 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Stage of Bioprocess
Table 15.19 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Scale of Operation
Table 15.20 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Year of Establishment
Table 15.21 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Company Size
Table 15.22 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Location of Headquarters
Table 15.23 Key Players: Distribution by Continuous Manufacturing Equipment for Biologic Drugs
Table 15.24 Technologies Involved: Hybrid vs Fully Integrated Continuous Technologies
Table 15.25 Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocessing Techniques, 2021-2030 (USD Billion)
Table 15.26 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (Range of Capacity)
Table 15.27 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (in Kg/Year)
Table 15.28 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Type of Manufacturer (in Kg/Year)
Table 15.29 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size and Type of Manufacturer (in Kg/Year)
Table 15.30 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Scale of Operation (in Kg/Year)
Table 15.31 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Headquarters (in Kg/Year)
Table 15.32 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Continuous and Semi-Continuous Bioprocessing Facilities (in Kg/Year)
Table 15.33 Overall Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030
Table 15.34 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Table 15.35 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
Table 15.36 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 15.37 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Stage of Bioprocess (USD Million)
Table 15.38 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Table 15.39 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.40 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Table 15.41 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
Table 15.42 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 15.43 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Table 15.44 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.45 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Table 15.46 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
Table 15.47 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 15.48 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)

List Of Companies

1. 3D Biotek
2. 3P Biopharmaceuticals
3. AbbVie 
4. ABL Europe
5. Abzena 
6. Accenture 
7. AGC Biologics
8. AIM ImmunoTech 
9. Alexanderwerk 
10. Alvotech
11. Amgen
12. AmpTec
13. Applikon Biotechnology
14. Aprogen
15. AstraZeneca
16. Avid Bioservices (formerly Peregrine Pharmaceuticals)
17. Baxter
18. Bayer
19. bbi-biotech
20. BIBITEC
21. BINEX
22. Biogen
23. BioMarin Pharmaceutical
24. Bionova Scientific
25. BiosanaPharma 
26. Bio-Thera Solutions 
27. Biovian
28. bluebird bio
29. Boehringer Ingelheim BioXcellence 
30. Bonumose 
31. Bristol-Myers Squibb
32. Changchun High & New Technology 
33. Canton Biologics
34. CCHT Biopharmaceutical
35. Celgene 
36. Cell and Gene Therapy Catapult 
37. Cell Culture Company
38. CELLEC Biotek
39. Celonic
40. Centre for Process Innovation (CPI)
41. Cerbios-Pharma
42. CMAC 
43. Cobra Biologics 
44. Codiak BioSciences
45. Coperion
46. Creative Biolabs
47. CSL Behring
48. Cytiva
49. Cytovance Biologics
50. DCI-Biolafitte 
51. DEVEX Verfahrenstechnik
52. DSM Pharmaceutical
53. Durham University
54. Eli Lilly
55. Engage Therapeutics (Acquired by UCB Pharma)
56. Enzene Biosciences
57. Eppendorf
58. Esco Aster
59. ETH Zurich
60. EV Biologics
61. Evotec
62. Exelixis 
63. Exothera
64. Forbius 
65. FUJIFILM Diosynth Biotechnologies
66. Gallus BioPharmaceuticals (Acquired by Patheon)
67. G-CON Manufacturing
68. GEA 
69. Genzyme
70. Global BioTherapeutics (GBT)
71. Glycotope 
72. Goodwin Biotechnology
73. GTP Technology
74. HAL Allergy
75. HALIX 
76. Handl Therapeutics
77. Hemispherx Biopharma
78. HJB
79. Horizon Therapeutics 
80. Janssen Pharmaceuticals
81. Johnson & Johnson 
82. Just-Evotec Biologics
83. KBI Biopharma
84. Kemwell Biopharma
85. Kiadisto 
86. Kymab
87. Lonza
88. Luina Bio
89. Lupin
90. MabSpace Biosciences 
91. Medix Biochemica
92. Merck
93. Merck KGaA
94. Microsoft 
95. MolMed 
96. Mycenax Biotech
97. MyoKardia (acquired by Bristol-Myers Squibb)
98. National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
99. National Resilience 
100. Natrix Separations (Acquired by Merck)
101. Nightstar Therapeutics (acquired by Biogen)
102. Novartis
103. Novasep
104. Novavax 
105. Novo Nordisk
106. Ology Bioservices 
107. OmniBRx Biotechnologies
108. OXGENE (Acquired by WuXi AppTec)
109. PacificGMP
110. Pall Biotech
111. Pall Life Sciences
112. Pfizer
113. Pierre Fabre 
114. PIERRE GUERIN
115. Polymun Scientific
116. ProBioGen
117. Rentschler Biopharma
118. Repligen 
119. Sage Therapeutics 
120. Samsung Biologics
121. Sangamo Therapeutics 
122. Sanofi Genzyme
123. Sartorius
124. Semba Biosciences
125. Servier
126. Shire
127. Sturtevant
128. Syngene
129. Synthecon
130. TA Instruments
131. ThalesNano
132. The Rockefeller University 
133. Thermo Fisher Scientific
134. Tidal Therapeutics (Acquired by Sanofi)
135. Transcenta 
136. Translate Bio
137. UCB Pharma
138. UIC College of Pharmacy
139. Universitas Indonesia 
140. University of Strathclyde
141. Vapourtec
142. Vigene Biosciences 
143. WuXi Biologics
144. WuXi STA 
145. XPure
146. YMC Process Technologies